Trial Profile
A Phase 1, Single-arm, Open-label Study To Confirm The Safety, Tolerability, And Immunogenicity Of A 4-antigen Staphylococcus Aureus Vaccine (sa4ag) In Healthy Adults Aged 18 To <65 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2017
Price :
$35
*
At a glance
- Drugs Staphylococcus aureus vaccine (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 28 Jan 2017 Results published in the Vaccine
- 02 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Feb 2015 New trial record